
## Ciro Celsa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5106307/publications.pdf Version: 2024-02-01



CIPO CELSA

#	Article	IF	CITATIONS
1	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Journal of Hepatology, 2019, 71, 265-273.	3.7	138
2	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 935-944.e3.	4.4	102
3	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut, 2022, 71, 593-604.	12.1	62
4	Diagnostic performance of endoscopic ultrasound throughâ€theâ€needle microforceps biopsy of pancreatic cystic lesions: Systematic review with metaâ€analysis. Digestive Endoscopy, 2020, 32, 1018-1030.	2.3	49
5	Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. Blood Advances, 2021, 5, 662-673.	5.2	42
6	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals, 2018, 11, 121.	3.8	41
7	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. International Journal of Molecular Sciences, 2019, 20, 5613.	4.1	39
8	Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: a systematic review and meta-analysis. Endoscopy, 2021, 53, 1037-1047.	1.8	39
9	Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 1061-1072.e8.	4.4	32
10	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	2.5	29
11	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. Liver Cancer, 2022, 11, 75-84.	7.7	29
12	Biliary complications after liver transplantation: current perspectives and future strategies. Hepatobiliary Surgery and Nutrition, 2021, 10, 76-92.	1.5	27
13	Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use. PLoS ONE, 2021, 16, e0245281.	2.5	25
14	Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE). Scientific Reports, 2021, 11, 1137.	3.3	22
15	Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. Future Oncology, 2019, 15, 3411-3422.	2.4	21
16	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. International Journal of Environmental Research and Public Health, 2019, 16, 4334.	2.6	21
17	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers, 2021, 13, 90.	3.7	21
18	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. Liver International, 2018, 38, 2108-2116.	3.9	20

CIRO CELSA

#	Article	IF	CITATIONS
19	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cancers, 2020, 12, 2132.	3.7	18
20	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine (United States), 2020, 99, e19958.	1.0	13
21	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. Liver International, 2021, 41, 1105-1116.	3.9	10
22	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers, 2021, 13, 897.	3.7	9
23	Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. Annals of Hepatology, 2021, , 100568.	1.5	8
24	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study Digestive and Liver Disease, 2021, 53, 1011-1019.	0.9	7
25	Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study. Endoscopic Ultrasound, 2021, 10, 440.	1.5	7
26	Consequences of Extended Spectrum Beta‣actamase–Producing Enterobacteriaceae and Methicillinâ€Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients. Liver Transplantation, 2021, 27, 43-54.	2.4	5
27	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. Cancers, 2021, 13, 592.	3.7	5
28	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Frontiers in Oncology, 2022, 12, 822507.	2.8	5
29	Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC. Diagnostics, 2022, 12, 1308.	2.6	4
30	Longâ€ŧerm evolution of Llâ€RADS observations in HCVâ€related cirrhosis treated with directâ€acting antivirals. Liver International, 2021, 41, 2179-2188.	3.9	3
31	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 3928-3938.	1.9	3
32	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International, 0, , .	1.3	3
33	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.9	3
34	Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data. Gastroenterology Insights, 2022, 13, 117-126.	1.2	3
35	Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1048-1053.	1.0	2
36	Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology. Gastrointestinal Endoscopy, 2020, 92, 237-238.	1.0	2

CIRO CELSA

#	Article	IF	CITATIONS
37	Editorial: proton pump inhibitor use in cirrhosis—a piece of the puzzle. Alimentary Pharmacology and Therapeutics, 2021, 53, 663-664.	3.7	2
38	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
39	Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?. Recenti Progressi in Medicina, 2018, 109, 605-608.	0.8	1
40	Systemic therapies for hepatocellular carcinoma: the present and the future. Recenti Progressi in Medicina, 2021, 112, 110-116.	0.8	1
41	Validation and refinement of PROSASH model using the neutrophilâ€ŧo″ymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International, 2020, 1, 6-11.	1.3	0
42	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
43	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
44	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
45	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
46	Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV	2.6	0

46 Eradication with Direct-Acting Antivirals. Diagnostics, 2022, 12, 1187.